Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Barinthus Biotherapeutics has announced its participation in the upcoming Investor Summit Virtual event scheduled for March 11, 2025. The company will be represented by CEO Bill Enright and CFO Gemma Brown at this significant investor conference.
Barinthus Biotherapeutics ha annunciato la sua partecipazione al prossimo evento Investor Summit Virtual previsto per l'11 marzo 2025. L'azienda sarà rappresentata dal CEO Bill Enright e dal CFO Gemma Brown in questa importante conferenza per investitori.
Barinthus Biotherapeutics ha anunciado su participación en el próximo evento Investor Summit Virtual programado para el 11 de marzo de 2025. La empresa estará representada por el CEO Bill Enright y la CFO Gemma Brown en esta importante conferencia para inversores.
Barinthus Biotherapeutics는 2025년 3월 11일에 예정된 Investor Summit Virtual 이벤트에 참여한다고 발표했습니다. 이 중요한 투자자 회의에서는 CEO Bill Enright와 CFO Gemma Brown이 회사의 대표로 참석할 것입니다.
Barinthus Biotherapeutics a annoncé sa participation au prochain événement Investor Summit Virtual prévu pour le 11 mars 2025. L'entreprise sera représentée par le PDG Bill Enright et la CFO Gemma Brown lors de cette importante conférence pour investisseurs.
Barinthus Biotherapeutics hat seine Teilnahme an der bevorstehenden Investor Summit Virtual Veranstaltung angekündigt, die für den 11. März 2025 geplant ist. Das Unternehmen wird durch CEO Bill Enright und CFO Gemma Brown auf dieser bedeutenden Investorenkonferenz vertreten sein.
- None.
- None.
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide the immune system to overcome autoimmunity and chronic infectious diseases. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a focused pipeline built around its proprietary platform technologies, Barinthus Bio is advancing immunotherapeutic product candidates in autoimmunity and infectious diseases, including: VTP-1000, utilizing the SNAP-Tolerance Immunotherapy (SNAP-TI) platform designed to treat people with celiac disease and VTP-300, that is utilizing the ChAdOx/MVA platform designed as a potential component of a functional cure for chronic HBV infection Further, it has license, research and development, and collaboration agreements with OUI, NIH, CanSino, CRUK; and Arbutus.
Event: Q1 Investor Summit
Presentation Time: 11:00 AM ET
Location: https://www.webcaster4.com/Webcast/Page/3082/52091
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who are significantly undervalued and have a near-term catalyst.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
Access Newswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESS Newswire
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact johnna-mae@investorsummitgroup.com
SOURCE: Barinthus Biotherapeutics plc
View the original press release on ACCESS Newswire